State Key Laboratory of Research & Development of Characteristic Qin Medicine Resources (Cultivation), and Shaanxi Key Laboratory of Chinese Medicine Fundamentals and New Drugs Research, and Shaanxi Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Shaanxi University of Chinese Medicine, Xi'an, 712046, China.
Xi'an Hospital of Traditional Chinese Medicine, Xi'an, 710021, China.
J Transl Med. 2022 Mar 18;20(1):135. doi: 10.1186/s12967-022-03329-3.
Urokinase-type plasminogen activator receptor (uPAR) is an attractive target for the treatment of cancer, because it is expressed at low levels in healthy tissues but at high levels in malignant tumours. uPAR is closely related to the invasion and metastasis of malignant tumours, plays important roles in the degradation of extracellular matrix (ECM), tumour angiogenesis, cell proliferation and apoptosis, and is associated with the multidrug resistance (MDR) of tumour cells, which has important guiding significance for the judgement of tumor malignancy and prognosis. Several uPAR-targeted antitumour therapeutic agents have been developed to suppress tumour growth, metastatic processes and drug resistance. Here, we review the recent advances in the development of uPAR-targeted antitumor therapeutic strategies, including nanoplatforms carrying therapeutic agents, photodynamic therapy (PDT)/photothermal therapy (PTT) platforms, oncolytic virotherapy, gene therapy technologies, monoclonal antibody therapy and tumour immunotherapy, to promote the translation of these therapeutic agents to clinical applications.
尿激酶型纤溶酶原激活物受体（uPAR）是癌症治疗的一个有吸引力的靶点，因为它在健康组织中低表达，但在恶性肿瘤中高表达。uPAR 与恶性肿瘤的侵袭和转移密切相关，在细胞外基质（ECM）的降解、肿瘤血管生成、细胞增殖和凋亡中发挥重要作用，与肿瘤细胞的多药耐药（MDR）有关，对肿瘤恶性程度和预后的判断具有重要的指导意义。已经开发了几种针对 uPAR 的抗肿瘤治疗药物来抑制肿瘤生长、转移过程和耐药性。在这里，我们综述了靶向 uPAR 的抗肿瘤治疗策略的最新进展，包括携带治疗药物的纳米平台、光动力疗法（PDT）/光热疗法（PTT）平台、溶瘤病毒治疗、基因治疗技术、单克隆抗体治疗和肿瘤免疫治疗，以促进这些治疗药物向临床应用的转化。
